Frontiers in Immunology (Jan 2023)

Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors

  • Xiaoqin Ji,
  • Wanrong Jiang,
  • Jiasheng Wang,
  • Bin Zhou,
  • Wei Ding,
  • Shuling Liu,
  • Hua Huang,
  • Guanhua Chen,
  • Xiangdong Sun

DOI
https://doi.org/10.3389/fimmu.2022.1106644
Journal volume & issue
Vol. 13

Abstract

Read online

Radiotherapy is one of the mainstays of cancer treatment. More than half of cancer patients receive radiation therapy. In addition to the well-known direct tumoricidal effect, radiotherapy has immunomodulatory properties. When combined with immunotherapy, radiotherapy, especially high-dose radiotherapy (HDRT), exert superior systemic effects on distal and unirradiated tumors, which is called abscopal effect. However, these effects are not always effective for cancer patients. Therefore, many studies have focused on exploring the optimized radiotherapy regimens to further enhance the antitumor immunity of HDRT and reduce its immunosuppressive effect. Several studies have shown that low-dose radiotherapy (LDRT) can effectively reprogram the tumor microenvironment, thereby potentially overcoming the immunosuppressive stroma induced by HDRT. However, bridging the gap between preclinical commitment and effective clinical delivery is challenging. In this review, we summarized the existing studies supporting the combined use of HDRT and LDRT to synergistically enhance antitumor immunity, and provided ideas for the individualized clinical application of multimodal radiotherapy (HDRT+LDRT) combined with immunotherapy.

Keywords